{"id":"https://openalex.org/W2280044053","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3530","title":"A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors","display_name":"A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors","publication_year":2009,"publication_date":"2009-05-20","ids":{"openalex":"https://openalex.org/W2280044053","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3530","mag":"2280044053"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.15_suppl.3530","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3530","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.3530","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017043037","display_name":"Andre Tesainer Brunetto","orcid":"https://orcid.org/0000-0002-7958-1279","observed_orcids":["https://orcid.org/0000-0002-7958-1279"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. T. Brunetto","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032749624","display_name":"Joo Ern Ang","orcid":"https://orcid.org/0000-0003-2103-996X","observed_orcids":["https://orcid.org/0000-0003-2103-996X"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. E. Ang","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012649978","display_name":"Rohit Lal","orcid":"https://orcid.org/0000-0002-2354-6618","observed_orcids":["https://orcid.org/0000-0002-2354-6618"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"R. Lal","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072116005","display_name":"David Olmos","orcid":"https://orcid.org/0000-0002-7003-4826","observed_orcids":["https://orcid.org/0000-0002-7003-4826"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Olmos","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049181098","display_name":"Sophia Frentzas","orcid":"https://orcid.org/0000-0002-6917-9737","observed_orcids":["https://orcid.org/0000-0002-6917-9737"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Frentzas","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100842452","display_name":"A. Mais","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Mais","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112051965","display_name":"B. Hauns","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"B. Hauns","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041894246","display_name":"Martin Mollenhauer","orcid":"https://orcid.org/0000-0002-3220-9269","observed_orcids":["https://orcid.org/0000-0002-3220-9269"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Mollenhauer","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108722032","display_name":"Gez Lahu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"G. Lahu","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. S. de Bono","raw_affiliation_strings":["Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, Sutton, United Kingdom; 4SC AG, Planegg-Martinsried, Germany; Nycomed GmbH, Konstanz, Germany","institution_ids":["https://openalex.org/I4210121186"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210121186"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"15_suppl","first_page":"3530","last_page":"3530"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10269","display_name":"Epigenetics and DNA Methylation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12465","display_name":"Cancer, Lipids, and Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.8960000276565552},{"id":"https://openalex.org/keywords/pan-hdac-inhibitors","display_name":"pan-HDAC inhibitors","score":0.9259999990463257},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8460000157356262},{"id":"https://openalex.org/keywords/refractory-cancer","display_name":"refractory cancer","score":0.7419999837875366},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.800000011920929},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.890999972820282},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9559999704360962},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7229999899864197},{"id":"https://openalex.org/keywords/histone-h4-acetylation","display_name":"histone H4 acetylation","score":0.9269999861717224},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.6740000247955322},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.7350000143051147},{"id":"https://openalex.org/keywords/liposarcoma","display_name":"liposarcoma","score":0.8399999737739563},{"id":"https://openalex.org/keywords/thymoma","display_name":"thymoma","score":0.996999979019165}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8622926473617554},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.7983452677726746},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.7192935347557068},{"id":"https://openalex.org/C2777054765","wikidata":"https://www.wikidata.org/wiki/Q6402731","display_name":"Dysgeusia","level":3,"score":0.7033505439758301},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6765860915184021},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6548277139663696},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6191422939300537},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.605211079120636},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5305650234222412},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5108551383018494},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.5063146352767944},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.46949532628059387},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4675622880458832},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4480687081813812},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.44745251536369324},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3972419798374176},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3470410108566284},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2009.27.15_suppl.3530","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3530","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.3530","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2793845487","https://openalex.org/W603336398","https://openalex.org/W7074008781","https://openalex.org/W2736123227","https://openalex.org/W2135619784","https://openalex.org/W2740702151","https://openalex.org/W7065716705","https://openalex.org/W2589922185","https://openalex.org/W2097589930","https://openalex.org/W4390175004"],"abstract_inverted_index":{"3530":[0],"Background:":[1],"4SC-201":[2,218,265],"(former":[3],"code":[4],"BYK408740)":[5],"is":[6,281],"a":[7,31,97,205,232,278],"specific,":[8],"potent,":[9],"pan-HDAC":[10],"inhibitor":[11],"with":[12,19,40,96,187,191,204,292],"improved":[13],"ADME":[14],"properties.":[15],"Methods:":[16],"Patients":[17],"(pts)":[18],"advanced":[20],"refractory":[21],"solid":[22],"tumors":[23],"were":[24,48,73,82,105,127,202],"dosed":[25,149],"once":[26],"daily":[27],"(QD)":[28],"d1\u20135":[29,276],"in":[30,34,146,166,231,277],"14-day":[32,279],"cycle":[33,280],"sequential":[35],"cohorts":[36,171],"of":[37,60,90,100,141,162,179,216,227],"3\u20136":[38],"pts":[39,94,112,122,126,164],"50":[41,245],"or":[42],"100%":[43],"dose":[44,58,109,261],"increments.":[45],"Primary":[46],"objectives":[47],"to":[49,222,246],"determine":[50],"safety,":[51],"tolerability,":[52],"pharmacokinetics":[53],"(PK)":[54],"and":[55,66,70,80,88,118,120,131,143,159,169,189,209,242,269],"maximum":[56],"tolerated":[57],"(MTD)":[59],"4SC-201.":[61],"Pharmacodynamic":[62],"assessment":[63],"(histone":[64],"acetylation":[65,252],"HDAC":[67,228],"enzyme":[68],"activity)":[69],"anti-tumor":[71],"efficacy":[72],"secondary":[74],"objectives.":[75],"Blood":[76],"samples":[77],"for":[78,129,283],"PK":[79,200],"PD":[81],"taken":[83],"on":[84],"days":[85],"1,":[86],"5":[87],"47":[89],"treatment.":[91],"Results:":[92],"18":[93],"(9M/9F)":[95],"median":[98],"age":[99],"58.5":[101],"yrs":[102],"(range":[103],"40\u201370)":[104],"treated":[106,165],"at":[107,114,123,133,150],"five":[108],"levels:":[110],"3":[111,139],"each":[113],"100mg,":[115],"200mg,":[116],"400mg":[117],"600mg":[119,168,274],"6":[121,198],"800mg.":[124,151],"All":[125],"evaluable":[128],"toxicity":[130],"received":[132],"least":[134],"2":[135],"treatment":[136,183,196],"cycles.":[137],"Grade":[138],"DLT":[140],"nausea":[142],"vomiting":[144,158],"occurred":[145],"1":[147],"pt":[148],"Most":[152],"common":[153],"adverse":[154],"events":[155],"included":[156],"nausea,":[157],"fatigue.":[160],"8":[161],"9":[163],"the":[167,176,180],"800mg":[170],"had":[172],"stable":[173],"disease":[174],"during":[175],"main":[177],"phase":[178,284],"study":[181],"(4":[182],"cycles).":[184],"A":[185],"patient":[186],"liposarcoma":[188],"another":[190],"thymoma":[192],"(marginal":[193],"response)":[194],"continued":[195],"beyond":[197],"months.":[199],"parameters":[201],"dose-proportional":[203],"low":[206],"inter-individual":[207],"variability":[208],"indicated":[210],"good":[211],"bioavailability.":[212],"The":[213,225],"apparent":[214],"t1/2":[215],"oral":[217],"ranged":[219],"from":[220,244],"2.3":[221],"4.4":[223],"hours.":[224],"degree":[226],"inhibition":[229],"measured":[230],"peripheral":[233],"blood":[234],"mononuclear":[235],"cell":[236],"functional":[237],"assay":[238],"was":[239],"dose-":[240],"dependent":[241],"increased":[243],"100":[247],"%,":[248],"although":[249],"histone":[250],"H4":[251],"accumulation":[253],"after":[254],"dosing":[255],"did":[256],"not":[257],"differ":[258],"significantly":[259],"between":[260],"levels.":[262],"Conclusions:":[263],"Oral":[264],"has":[266],"favorable":[267],"disposition":[268],"can":[270],"be":[271],"safely":[272],"administered;":[273],"QD":[275],"recommended":[282],"II":[285],"evaluation.":[286],"Safely":[287],"administered":[288],"doses":[289],"modulate":[290],"target":[291],"antitumor":[293],"activity.":[294],"[Table:":[295],"see":[296],"text]":[297]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2013,"cited_by_count":3}],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2016-06-24T00:00:00"}